Department of Gastroenterology, Peking University Third Hospital, No. 49 North Garden Rd., Haidian District, Beijing 100191, China.
Department of Pathology, Peking University Health Science Center, No. 38 Xueyuan Rd., Haidian District, Beijing 100191, China.
Biomed Res Int. 2019 Apr 3;2019:4530203. doi: 10.1155/2019/4530203. eCollection 2019.
Effects of the microbiome associated with diarrhea-predominant irritable bowel syndrome (IBS-D) on the gut have been reported, but no study has reported the effects of the IBS-D gut microbiome on the liver. We transplanted the fecal microbiota from an IBS-D patient and from a healthy volunteer to GF rats. The hepatic inflammation, serum biochemical parameters and metabolome, fecal microbiota profile, fecal short-chain fatty acids (SCFAs), and correlations among them before and after berberine intervention were assessed. Compared with the healthy control fecal microbiome transplantation (FMT) rats, the fecal microbiota of IBS-D patients induces significant Kupffer cell hyperplasia, hepatic sinusoid hypertrophy, and elevated levels of hepatic tumor necrosis factor- and interferon- and decreases the synthesis of ALB in GF rats. This is possibly related to and attributable to fecal formate, acetate, and propionate levels, which are associated with the host linoleic acid pathway. Berberine can partially reverse the Kupffer cell hyperplasia, , fecal formate, acetate, and propionate by modulating the gut microbiome composition. These results may imply that IBS-D not only is an intestinal functional disorder but can cause liver inflammation, thus providing some implications regarding the clinical cognition and treatment of IBS-D.
与腹泻为主型肠易激综合征(IBS-D)相关的微生物组对肠道的影响已有报道,但尚无研究报道 IBS-D 肠道微生物组对肝脏的影响。我们将来自 IBS-D 患者和健康志愿者的粪便微生物群移植到 GF 大鼠中。评估了大黄素干预前后肝炎症、血清生化参数和代谢组学、粪便微生物群谱、粪便短链脂肪酸(SCFA)以及它们之间的相关性。与健康对照粪便微生物群移植(FMT)大鼠相比,IBS-D 患者的粪便微生物群诱导 GF 大鼠中库普弗细胞增生、肝窦扩张和肝肿瘤坏死因子和干扰素水平升高,并降低 ALB 的合成。这可能与粪酸盐、乙酸盐和丙酸盐水平有关,这些水平与宿主亚油酸途径有关。大黄素通过调节肠道微生物群组成,可部分逆转库普弗细胞增生、、粪酸盐、乙酸盐和丙酸盐。这些结果可能意味着 IBS-D 不仅是一种肠道功能障碍,还会引起肝脏炎症,从而为 IBS-D 的临床认知和治疗提供一些启示。
Neurogastroenterol Motil. 2012-2-22
Pharmaceuticals (Basel). 2025-1-31
J Gastroenterol Hepatol. 2024-12
Environ Microbiol. 2018-9-24
Nat Rev Gastroenterol Hepatol. 2018-7
J Gastroenterol Hepatol. 2018-6-3
Hepatology. 2018-10
Best Pract Res Clin Gastroenterol. 2017-9-18
GE Port J Gastroenterol. 2018-1